Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Aston

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
The Oncologist|March 1, 2018
Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell CarcinomaRenee K McAlister, Jonathan Aston, Megan Pollack, et al.
Lung Cancer (Amsterdam, Netherlands)|January 19, 2016
Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆Megan L Hames, Heidi Chen, Wade Iams, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 22, 2014
Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomasHelena A Yu, Camelia S Sima, Ronglai Shen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 9, 2017
NCCN Guidelines Insights: Antiemesis, Version 2.2017Michael J Berger, David S Ettinger, Jonathan Aston, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
The Oncologist|March 1, 2018
Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell CarcinomaRenee K McAlister, Jonathan Aston, Megan Pollack, et al.
Lung Cancer (Amsterdam, Netherlands)|January 19, 2016
Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆Megan L Hames, Heidi Chen, Wade Iams, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 22, 2014
Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomasHelena A Yu, Camelia S Sima, Ronglai Shen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 9, 2017
NCCN Guidelines Insights: Antiemesis, Version 2.2017Michael J Berger, David S Ettinger, Jonathan Aston, et al.
Pageof 1